« Back
Home /
WEHI-539

WEHI-539

Item no.	HY-15607-50mg
Manufacturer	MedChem Express
CASRN	1431866-33-9
Amount	50 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Uterine, Ovarian & Cervical Cancer
Type	Inhibitors
Specific against	other
Purity	95.05
Citations	[1]Lessene G, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013 Jun;9(6):390-7.\|[2]Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25. Am J Cancer Res. 2019 Dec 1;9(12):2580-2598.\|Breast Cancer Res Treat. 2019 Feb;173(3):585-596.\|Cancer Biology. 2020 May.\|Cell Death Differ. 2014 Jul;21(7):1170-7. \|Cell Death Differ. 2017 Jan;24(1):111-119. \|Cell Death Dis. 2017 Dec 13;8(12):3216.\|Cell Death Dis. 2023 Oct 28;14(10):705.\|Cell. 2014 Dec 18;159(7):1549-62.\|Clin Cancer Res. 2019 Dec 1;25(23):7139-7150. \|J Ovarian Res. 2016 Apr 14;9(1):25. \|Nat Commun. 2016 Mar 9;7:10916.\|Nature. 2017 Nov 9;551(7679):247-250. \|Oncol Rep. 2019 Dec;42(6):2416-2425.\|Pharmacol Res. 2022 Dec 21;187:106628.\|Acta Pharmacol Sin. 2024 Aug 26.\|bioRxiv. 2023 Aug 5.\|Blood. 2014 Dec 4;124(24):3587-96. \|Cell Death Dis. 2018 Jan 19;9(2):42.\|Cell Rep. 2023 Mar 30;42(4):112324.\|Cell. 2014 Dec 18;159(7):1549-62.\|Immunity. 2024 Jun 11;57(6):1289-1305.e9.\|Int J Cancer. 2018 Feb 1;142(3):584-596.\|Malays Appl Biol. (2020) 49(1): 193-197.\|Methods Mol Biol. 2018;1711:351-398.\|Nat Biotechnol. 2018 Feb;36(2):179-189.\|Nat Cancer. 2024 May 30.\|Nat Chem Biol. 2022 Jun;18(6):615-624.\|Nature. 2017 Nov 9;551(7679):247-250. \|Oncotarget. 2018 May 25;9(40):26046-26063.\|The Department of Medical Sciences, Harvard University. 2019 Dec.
Smiles	OC(C1=C(CCCOC2=CC=C(CN)C=C2)SC(C3=CC4=C(CCC/C4=N\NC5=NC(C=CC=C6)=C6S5)C=C3)=N1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1431866-33-9
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Bcl-2 Family
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	583.72
Product Description	WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.
Manufacturer - Research Area	Cancer
Solubility	10 mM in DMSO
Manufacturer - Pathway	Apoptosis
Isoform	Bcl-xL
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 50 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question